Titanium Rib (Vertical Expandable Prosthetic Titanium Rib — VEPTR)
Customize your policy alerts
Sign up for Aetna Policy 0582 alerts
Get alerted when Policy 0582 changes without checking for updates manually.
Monitor payer policy activity
Clinical policy governing use of the vertical expandable prosthetic titanium rib (VEPTR/titanium rib) for treatment of thoracic insufficiency syndrome and other indications, addressing medical necessity, investigational uses, and applicable coding guidance for Aetna members/providers.
No material clinical or coverage changes in this revision.
Coverage criteria for VEPTR (Vertical Expandable Prosthetic Titanium Rib)
Medical Necessity — VEPTR for Thoracic Insufficiency Syndrome
Covered when ALL of the following are met
TIS may include flail chest, rib fusion with scoliosis, or hypoplastic thorax syndromes (eg, achondroplasia, Ellis van Creveld, Jarcho-Levin, Jeune's)
Experimental and Investigational
Not covered/considered investigational
Insufficient evidence in the peer-reviewed literature
Evidence summary / clinical criteria
Evidence-based findings and outcome patterns reported
Supported across multiple observational studies and case series
Examples include significant increases in T1–T12 and T1–S1 heights and percent of expected growth at 2-year follow-up
Examples: 41 complications in a 25-patient series; 65% 2-year complication rate in one comparative study; 56% of patients had ≥1 unplanned re-operation in a cohort; OR=3.05 for unplanned re-operation age 0–2 vs 3–10
Examples: TGR produced greater curve correction and thoracic height gain and lower wound complication rates; MCGR had significantly fewer complications and re-operations at 2 years versus VEPTR
Authors call for longer-term, multi-center prospective studies to assess sustained benefits and long-term survival
The U.S. Food and Drug Administration (FDA) has granted humanitarian device approval for the VEPTR for treatment of thoracic insufficiency syndrome (TIS). The FDA also lists specific device contraindications that should be considered when evaluating candidates: absence of proximal ribs for attachment, absent diaphragmatic function, age below 6 months, age beyond skeletal maturity, inadequate soft tissue for coverage, inadequate bone strength (ribs/spine) for attachment, infection at the operative site, and known allergy to device materials.
High-quality randomized controlled trials are lacking for many surgical strategies in congenital and early-onset scoliosis; reviewers have not identified prospective RCT evidence supporting routine early spinal fusion in congenital scoliosis. Given the limited prospective data, conservative measures (for example, advanced bracing or serial casting where appropriate) are advocated and should be considered before proceeding to invasive, growth-preserving procedures in selected patients.
Although VEPTR was originally developed to treat TIS and improve respiratory function, the literature highlights challenges in assessing pulmonary benefit and notes that long-term outcomes remain incompletely characterized. Authors emphasize cautious patient selection and the need for more robust, long-term comparative studies to guide timing of intervention.
No additional explicit coverage-limit statements or exclusion criteria are stated in this portion of the document beyond the FDA contraindications and the investigational language for non‑TIS indications. Clinical reviewers should rely on the documented FDA contraindications and the policy’s stated medical‑necessity criteria when evaluating requests.
Use of VEPTR for treatment of scoliosis in the absence of thoracic insufficiency syndrome (TIS) is considered experimental/investigational and not medically necessary. Prior authorization and coverage decisions should reflect that VEPTR is indicated primarily for skeletally immature patients with documented TIS, not for isolated scoliotic deformity without thoracic compromise.
Reports in the recent literature describe a progressive decline in use of VEPTR at some centers in favor of spine‑based growing-rod systems (traditional growing rods [TGR] and magnetically controlled growing rods [MCGR]). Reasons cited include identification of extra‑spinal ossifications and other device-related complications with VEPTR, the availability of motorized distraction implants that avoid repetitive open lengthenings, and comparative studies reporting greater thoracic height gain and lower wound‑complication rates with spine‑based alternatives.
There are no explicit additional statements in this document segment that declare other services specifically not medically necessary beyond the investigational designation for non‑TIS indications; reviewers should apply the policy’s defined medical necessity criteria and supporting exclusions.
Billing and diagnosis coding for VEPTR
| M41.00 - M41.9 | Scoliosis [if resulting in thoracic insufficiency syndrome] |
| M96.5 | |
| M95.4 | Acquired deformity of chest and rib [if resulting in thoracic insufficiency syndrome] |
| Q67.5 | Congenital deformity of spine [if resulting in thoracic insufficiency syndrome] |
| Q76.3 | Congenital scoliosis due to congenital bony malformation [if resulting in thoracic insufficiency syndrome] |
| Q76.6 | Other congenital malformations of ribs [if resulting in thoracic insufficiency syndrome] |
| Q76.7 | Congenital malformation of sternum [if resulting in thoracic insufficiency syndrome] |
| Q78.9 | Osteochondrodysplasia, unspecified [if resulting in thoracic insufficiency syndrome] |
| Q77.6 | Chondroectoderman dysplasia [if resulting in thoracic insufficiency syndrome] |
| S22.5XX+ | Flail chest [if resulting in thoracic insufficiency syndrome] |
| M40.00 - M40.299 | Kyphosis |
| Q76.411 - Q76.419 | Congenital kyphosis |
| Q79.8 | Other congenital malformations of musculosketetal system [Poland syndrome] |
| H030009 | FDA Humanitarian Device Exemption number for VEPTR (identifier in FDA summary) |
Provider actions, prior authorization, and documentation requirements
Prior authorization required for VEPTR when medical necessity met
Prior authorization is expected for VEPTR placement when medical necessity criteria for thoracic insufficiency syndrome in a skeletally immature patient are met; note that there is no specific CPT/HCPCS code for VEPTR.
Document indication, baseline measures, and device rationale
When requesting prior authorization, document the clinical indication (for example progressive early-onset scoliosis with thoracic insufficiency syndrome), baseline radiographic curve measurements and spinal height, and the clinical rationale for selecting a rib-based VEPTR device versus alternative growth-friendly systems.
- Indication (e.g., progressive EOS with TIS)
- Baseline Cobb angle and T1–T12/T1–S1 heights
- Justification for rib-based VEPTR versus spine-based growing rods
Prior authorization: required clinical details
Prior authorization submissions should include the indication for VEPTR, the patient’s age at intended implantation, and evidence that alternative growth-friendly techniques and conservative management were considered given reports of higher unplanned re-operation rates in younger patients.
- Patient age at intended implantation
- Discussion of alternatives and rationale for VEPTR
Consider and document conservative therapy first
Conservative measures such as bracing or serial body casting are generally considered before VEPTR for some infantile scoliosis presentations and should be documented where applicable.
- Bracing outcome and duration
- Serial casting attempts and response
Consider conservative management and device sequencing
Consider sequencing care to try conservative management and/or spine-based growing rod alternatives (traditional or magnetically controlled growing rods) before VEPTR, and document why VEPTR is preferred when alternatives may offer greater thoracic height gain or lower wound-complication rates in some studies.
- Comparison to TGR/MCGR outcomes (curve correction, thoracic height, wound complications)
- Reason for selecting VEPTR despite alternative device evidence
Associate appropriate ICD-10 codes for TIS
ICD-10 diagnosis codes indicating thoracic insufficiency syndrome or its causes should be associated with the claim; examples include M41.00–M41.9, M95.4, Q67.5, Q76.3, Q76.6, Q76.7, Q78.9, Q77.6, and S22.5XX+.
Required clinical documentation elements
Clinical documentation supporting the indication must include the diagnosis (eg, thoracic insufficiency syndrome, EOS, congenital or neuromuscular scoliosis), prior conservative management status, radiographic measures (Cobb angles, T1–T12 and T1–S1 heights, SAL), and history of prior procedures or implants.
- Diagnosis and scoliosis etiology
- Prior conservative therapy (bracing, casting) and outcomes
- Radiographic measures: Cobb angle, T1–T12 and T1–S1 heights, SAL
- Prior spine procedures or implants
Suggested documentation: age, indication, and risk discussion
Suggested documentation should explicitly state patient age at implantation, the indication (for example TIS or congenital scoliosis), and a discussion of risks including the higher unplanned reoperation rates reported in patients implanted at age 0–2.
- Patient age at implantation
- Discussion of risk of unplanned re-operation, especially age 0–2
Risk of denial if TIS is not documented
Use of VEPTR for scoliosis or other indications in the absence of thoracic insufficiency syndrome is considered experimental/investigational and may be denied.
Denial risk from complications and limited evidence
High complication rates reported in the literature and limited prospective evidence for some indications (for example congenital scoliosis) may influence coverage decisions and increase risk of denial if not addressed in documentation.
- Document known complication risks and rationale for surgery
- Provide evidence supporting expected benefit for the patient
Denial risk tied to higher re-operation rates in very young patients
Higher unplanned re-operation rates—particularly in patients implanted between 0 and 2 years of age—have been reported; lack of documentation justifying early implantation may increase likelihood of coverage denial.
- Report shows patients age 0–2 had higher odds (OR=3.05) of unplanned re-operation versus age 3–10
- Document rationale if implantation is planned before age 3
Background on VEPTR and clinical context
The vertical expandable prosthetic titanium rib (VEPTR) is an implanted, expandable titanium chest‑wall distractor developed for use in expansion thoracoplasty. It is intended to expand a constricted hemithorax and improve lung capacity in skeletally immature patients with thoracic insufficiency syndrome (TIS). The device has been used to indirectly address associated spinal deformity in young children while allowing continued thoracic and spinal growth, and it holds a FDA humanitarian device approval specifically for TIS.
Definitions and terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.